| |
著者: D Capone, G Tarantino, A Gentile, M Sabbatini, G Polichetti, M Santangelo, R Nappi, A Ciotola, V D'Alessandro, A Renda, V Basile, S Federico
雑誌名: J Clin Pharm Ther. 2010 Feb;35(1):121-4. doi: 10.1111/j.1365-2710.2009.01070.x.
Abstract/Text
Infection occurs frequently in the organ transplant recipients during the post-transplant period because of immunosuppression. Therefore, prophylactic antimicrobial agents are often used. The azole antifungals, widely prescribed prophylactically, are known to have many drug-drug interactions. This report presents a case of drug-drug interaction between voriconazole and tacrolimus in a kidney transplant recipient. Voriconazole treatment led to a dramatic increase in tacrolimus concentration that required its discontinuation in spite of the manufacturer's guidelines that recommend a reduction of tacrolimus dosage by one-third. The present drug-drug interaction can be attributed to a strong inhibitory effect on cytochrome P450-3A4 activity by voriconazole. When voriconazole and tacrolimus are coadministered, close monitoring of tacrolimus blood levels is recommended as the rule-of-thumb reduction of tacrolimus dose by one-third may not be satisfactory.
PMID 20175821 J Clin Pharm Ther. 2010 Feb;35(1):121-4. doi: 10.1111/j.1365-2710.2009.01070.x.
|
